Gastric cancer genome profiling reveals HER2 false-negative status and informs a successful trastuzumab treatment strategy
-
- WADA Hironori
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- FUJINO Yasuteru
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- KAGEMOTO Kaizo
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- KIDA Yoshifumi
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- OKADA Yasuyuki
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- MITSUI Yasuhiro
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- OKAMOTO Koichi
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- SATO Yasushi
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- BANDO Yoshimi
- Division of Pathology, Tokushima University Hospital
-
- MIYAMOTO Hiroshi
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
-
- TAKAYAMA Tetsuji
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Science
Bibliographic Information
- Other Title
-
- がん遺伝子パネル検査を契機にHER2陽性が判明しTrastuzumab投与により長期生存が得られた進行胃癌の1例
Search this article
Abstract
<p>Intratumoral HER2 heterogeneity is a well-described gastric cancer feature and may explain many false-negative results related to this oncogene. An 81-year-old man was diagnosed at our hospital with stage IV gastric cancer with multiple lymph node metastases. Immunohistochemistry (IHC) analysis indicated that the primary tumor was HER2-negative. After a chemotherapy course, we submitted a pretreatment biopsy specimen for comprehensive cancer genome profiling (CGP) to determine the last-line therapy. This revealed HER2 amplification. The specimen was reevaluated using fluorescence in situ hybridization and IHC with deeper-cut specimens, which confirmed that the tumor was indeed HER2-positive. Therefore, the patient was treated with chemotherapy plus trastuzumab, which elicited tumor shrinkage and conferred long-term survival. Our current data underscore the CGP importance, which can provide more accurate tumor profilings and inform subsequent treatment decisions.</p>
Journal
-
- Nippon Shokakibyo Gakkai Zasshi
-
Nippon Shokakibyo Gakkai Zasshi 119 (10), 937-945, 2022-10-10
The Japanese Society of Gastroenterology
